68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and
monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors,
medullary thyroid cancer and other cancers expressing somatostatin receptors.